NO991074D0 - En metode for Õ fremstille birnavirus fra syntetiske RNA-transkripter - Google Patents

En metode for Õ fremstille birnavirus fra syntetiske RNA-transkripter

Info

Publication number
NO991074D0
NO991074D0 NO991074A NO991074A NO991074D0 NO 991074 D0 NO991074 D0 NO 991074D0 NO 991074 A NO991074 A NO 991074A NO 991074 A NO991074 A NO 991074A NO 991074 D0 NO991074 D0 NO 991074D0
Authority
NO
Norway
Prior art keywords
virus
segments
rna
ibdv
transfection
Prior art date
Application number
NO991074A
Other languages
English (en)
Other versions
NO991074L (no
Inventor
Vikram N Vakharia
Egbert Mundt
Original Assignee
Univ Maryland Biotech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Biotech Inst filed Critical Univ Maryland Biotech Inst
Publication of NO991074D0 publication Critical patent/NO991074D0/no
Publication of NO991074L publication Critical patent/NO991074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19991074A 1996-09-05 1999-03-04 En metode for a fremstille birnavirus fra syntetiske RNA-transkripter NO991074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/708,541 US5871744A (en) 1996-09-05 1996-09-05 Method for generating birnavirus from synthetic RNA transcripts
PCT/US1997/012955 WO1998009646A1 (en) 1996-09-05 1997-07-31 A method for generating birnavirus from synthetic rna transcripts

Publications (2)

Publication Number Publication Date
NO991074D0 true NO991074D0 (no) 1999-03-04
NO991074L NO991074L (no) 1999-04-29

Family

ID=24846203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991074A NO991074L (no) 1996-09-05 1999-03-04 En metode for a fremstille birnavirus fra syntetiske RNA-transkripter

Country Status (18)

Country Link
US (1) US5871744A (no)
EP (2) EP0959901A4 (no)
JP (1) JP4670025B2 (no)
KR (1) KR100475427B1 (no)
CN (1) CN1168500C (no)
AT (1) ATE460178T1 (no)
AU (1) AU741055B2 (no)
BR (1) BR9712012B1 (no)
CA (1) CA2264488C (no)
CZ (1) CZ299417B6 (no)
DE (1) DE69739805D1 (no)
ES (1) ES2342325T3 (no)
HU (1) HUP9904365A3 (no)
IL (2) IL128804A0 (no)
NO (1) NO991074L (no)
NZ (1) NZ334667A (no)
PL (1) PL190220B1 (no)
WO (1) WO1998009646A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596280B1 (en) * 1997-07-31 2003-07-22 University Of Maryland Biotechnology Institute Method for generating birnavirus from synthetic RNA transcripts
WO1999050419A2 (en) * 1998-03-31 1999-10-07 University Of Maryland Biotechnology Institute A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts
WO2000012677A2 (en) * 1998-09-01 2000-03-09 The University Of Hong Kong Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
HUP9802974A1 (hu) * 1998-12-19 2000-09-28 Mezőgazdasági Biotechnológiai Kutatóközpont Fertőző bursitis elleni DNS-vakcina
US6492148B1 (en) * 1999-03-05 2002-12-10 Akzo Nobel Nv Genetically engineered cell culture adapted infectious bursal disease virus (IBDV) mutants
US6468984B1 (en) 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus
EP1069187A1 (en) * 1999-07-14 2001-01-17 Stichting Dienst Landbouwkundig Onderzoek Mosaic Infectious Bursal Disease Virus vaccines
US7431930B2 (en) * 2002-03-01 2008-10-07 Intervet International B.V. Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
US7244432B2 (en) * 2004-12-08 2007-07-17 University Of Maryland Biotechnology Institute Infectious bursal disease virus (IBDV) variant from Georgia
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
KR100757541B1 (ko) * 2005-11-08 2007-09-10 엘지전자 주식회사 플라즈마 디스플레이 장치 및 그의 화상 처리방법
WO2008068661A1 (en) * 2006-12-01 2008-06-12 Hepc Biotechnológiai Kutató És Fejleszto Kft. Compositions and methods for the treatment of viral hepatitis
CN101016547B (zh) * 2007-01-25 2010-07-28 浙江大学 海洋双rna病毒mabv重组蛋白的制备方法与应用
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
CN109321583B (zh) * 2018-09-29 2023-08-15 福建省农业科学院畜牧兽医研究所 一种构建番鸭呼肠孤病毒反向遗传系统的方法
AU2020329166A1 (en) 2019-08-09 2022-03-03 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
CA1334941C (en) * 1985-05-30 1995-03-28 Ahmed Azad Azad Cloning and expression of a host-protective immunogens of ibdv
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US5192539A (en) * 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5518724A (en) * 1988-08-02 1996-05-21 University Of Maryland Infectious bursal disease virus
NZ235474A (en) * 1989-10-18 1992-12-23 Univ Maryland Virus capable of inducing infectious bursal disease; assay and vaccine
JPH05501064A (ja) * 1990-05-04 1993-03-04 ユニバーシティ　オブ　メリーランド　アット　カレッジ　パーク Ｉｂｄｖタンパク質に関連する特異的ｄｎａ配列並びにベクター、宿主およびワクチン
EP0597016A4 (en) * 1991-07-26 1996-04-24 Virogenetics Corp Infectious bursal disease virus recombinant poxvirus vaccine.
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon

Also Published As

Publication number Publication date
CN1168500C (zh) 2004-09-29
IL128804A0 (en) 2000-01-31
NO991074L (no) 1999-04-29
NZ334667A (en) 2000-09-29
IL128804A (en) 2006-08-01
ATE460178T1 (de) 2010-03-15
BR9712012B1 (pt) 2009-08-11
HUP9904365A2 (hu) 2000-04-28
JP4670025B2 (ja) 2011-04-13
KR100475427B1 (ko) 2005-03-10
CA2264488C (en) 2009-04-07
JP2001501082A (ja) 2001-01-30
WO1998009646A1 (en) 1998-03-12
US5871744A (en) 1999-02-16
CA2264488A1 (en) 1998-03-12
EP0959901A4 (en) 2002-11-04
DE69739805D1 (de) 2010-04-22
CN1229358A (zh) 1999-09-22
KR20010029487A (ko) 2001-04-06
PL332184A1 (en) 1999-08-30
BR9712012A (pt) 2000-01-18
EP1930026A1 (en) 2008-06-11
CZ74299A3 (cs) 1999-08-11
EP1930026B1 (en) 2010-03-10
AU741055B2 (en) 2001-11-22
PL190220B1 (pl) 2005-11-30
AU3891897A (en) 1998-03-26
HUP9904365A3 (en) 2001-06-28
EP0959901A1 (en) 1999-12-01
CZ299417B6 (cs) 2008-07-16
ES2342325T3 (es) 2010-07-05

Similar Documents

Publication Publication Date Title
NO991074D0 (no) En metode for Õ fremstille birnavirus fra syntetiske RNA-transkripter
Mundt et al. Synthetic transcripts of double-stranded Birnavirus genome are infectious.
NO20082682L (no) En fremgangsmate for a fremstille ikke-patogene, infeksiose pancreatiske nekrosevirus (IPNC) fra syntetisk RNA-transkripter
Pilipenko et al. Prokaryotic-like cis elements in the cap-independent internal initiation of translation on picornavirus RNA
Iseni et al. Characterization of rabies virus nucleocapsids and recombinant nucleocapsid-like structures
Alonso et al. Transcription regulatory sequences and mRNA expression levels in the coronavirus transmissible gastroenteritis virus
Martin et al. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication
Dobos et al. The molecular biology of infectious pancreatic necrosis virus: a review
Yao et al. Generation of infectious pancreatic necrosis virus from cloned cDNA
de Haan et al. Coronaviruses as vectors: position dependence of foreign gene expression
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
Ozdarendeli et al. Downstream sequences influence the choice between a naturally occurring noncanonical and closely positioned upstream canonical heptameric fusion motif during bovine coronavirus subgenomic mRNA synthesis
Zhou et al. Establishment of reverse genetics system for infectious bronchitis virus attenuated vaccine strain H120
YU37502A (sh) Infektivni klonovi
Meyer et al. A novel type of defective viral genome suggests a unique strategy to establish and maintain persistent lymphocytic choriomeningitis virus infections
Kato et al. Sendai virus gene start signals are not equivalent in reinitiation capacity: moderation at the fusion protein gene
Lian et al. Recovery of infectious type Asia1 foot-and-mouth disease virus from suckling mice directly inoculated with an RNA polymerase I/II-driven unidirectional transcription plasmid
Yamasaki et al. Alternative translation initiation of Theiler’s murine encephalomyelitis virus
Dhanwani et al. Establishment of bisegmented and trisegmented reverse genetics systems to generate recombinant Pichinde viruses
Johnson et al. Effect of mutations in the mouse hepatitis virus 3′(+) 42 protein binding element on RNA replication
Derdeyn et al. Characterization of defective-interfering RNAs of rubella virusgenerated during serial undiluted passage
Graff et al. Influence of the 5′ noncoding region of hepatitis A virus strain GBM on its growth in different cell lines
Enjuanes et al. Virus-based vectors for gene expression in mammalian cells: Coronavirus
Grabau et al. Analysis of viral and defective-interfering nucleocapsids in acute and persistent infection by rhabdoviruses
US7279327B2 (en) Methods for producing recombinant coronavirus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application